Skip to main content

Table 3 Starting days and crude event rates for different macrolides and fluoroquinolones

From: Cardiac events after macrolides or fluoroquinolones in patients hospitalized for community-acquired pneumonia: post-hoc analysis of a cluster-randomized trial

Macrolides

Azithromycin

Clarithromycin

Erythromycin

Patients with antibiotic any time during admission

207

250

277

Starting day of antibiotic during admission¶

1 (0–2)

0 (0–1)

0 (0–0)

Percentage starting antibiotic intravenously §

263 (94.9%)

Cardiac event

a) Any type

11 (5.3%)

18 (7.2%)

31 (11.2%)

b) Heart failure

9 (4.3%)

14 (5.6%)

26 (9.4%)

c) Arrhythmia

6 (2.9%)

5 (2%)

10 (3.6%)

Fluoroquinolones

Ciprofloxacin

Levofloxacin

Moxifloxacin

Patients with antibiotic any time during admission

234*

194

566

Starting day of antibiotic during admission¶

1 (0–3)

0 (0–0)

0 (0–0)

Percentage starting antibiotic intravenously

76 (32.5%)

111 (57.2%)

394 (69.6%)

Cardiac event

a) Any type

9 (3.8%)

5 (2.6%)

23 (4.1%)

b) Heart failure

9 (3.8%)

3 (1.5%)

16 (2.8%)

c) Arrhythmia

5 (2.1%)

3 (1.5%)

11 (1.9%)

  1. Values are numbers (percentages) unless otherwise noted. ¶Median (interquartile range) *One patient received ofloxacin
  2. § Azithromycin and clarithromycin are not available for intravenous administration in the Netherlands